tirzepatide side effects rash Mounjaro® Skin & Management Tirzepatide Side Effects: What to

doi: 10.1016/j.cmet.2022.08.003 100 RicciALieszA

Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved

In fact, it's likely the opposite

G., Snchez, E., Romero, I., Vidal-Puig, A., Berral, F

Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 trial

highlighted the significant dose-dependent weight loss effects of retatrutide, as well as improvements in BMI, waist circumference, fasting plasma glucose, HbA1c, and blood pressure